Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 546

1.

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.

Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H.

Arch Neurol. 2007 Oct;64(10):1407-15. Epub 2007 Aug 13.

PMID:
17698695
[PubMed - indexed for MEDLINE]
2.

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.

Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L; BHT-3009 Study Group.

Ann Neurol. 2008 May;63(5):611-20. doi: 10.1002/ana.21370.

PMID:
18481290
[PubMed - indexed for MEDLINE]
3.

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.

Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, Dörr J, Waiczies H, Haertle M, Wernecke KD, Volk HD, Aktas O, Zipp F.

PLoS One. 2008 Apr 9;3(4):e1928. doi: 10.1371/journal.pone.0001928.

PMID:
18398457
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.

Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT.

Neurology. 2008 Oct 28;71(18):1390-5. doi: 10.1212/01.wnl.0000319698.40024.1c. Epub 2008 Jun 4.

PMID:
18525027
[PubMed - indexed for MEDLINE]
5.

DNA-based vaccines: the future of multiple sclerosis therapy?

Stüve O, Cravens PD, Eagar TN.

Expert Rev Neurother. 2008 Mar;8(3):351-60. doi: 10.1586/14737175.8.3.351. Review.

PMID:
18345967
[PubMed - indexed for MEDLINE]
6.

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.

Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.

Mult Scler. 2010 Apr;16(4):450-4. doi: 10.1177/1352458509358909. Epub 2010 Feb 11.

PMID:
20150398
[PubMed - indexed for MEDLINE]
7.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
[PubMed - indexed for MEDLINE]
8.

BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis.

Correale J, Fiol M.

Curr Opin Mol Ther. 2009 Aug;11(4):463-70.

PMID:
19649992
[PubMed - indexed for MEDLINE]
9.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
[PubMed - indexed for MEDLINE]
11.

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; MN166-001 Investigators.

Neurology. 2010 Mar 30;74(13):1033-40. doi: 10.1212/WNL.0b013e3181d7d651. Epub 2010 Mar 3.

PMID:
20200338
[PubMed - indexed for MEDLINE]
12.

Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis.

Hafler DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Fukaura H.

Ann N Y Acad Sci. 1997 Dec 19;835:120-31.

PMID:
9616767
[PubMed - indexed for MEDLINE]
13.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

PMID:
20089952
[PubMed - indexed for MEDLINE]
Free Article
14.

A DNA vaccine for multiple sclerosis.

Garren H.

Expert Opin Biol Ther. 2008 Oct;8(10):1539-50. doi: 10.1517/14712598.8.10.1539 . Review.

PMID:
18774921
[PubMed - indexed for MEDLINE]
15.

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.

Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.

Arch Neurol. 2008 Feb;65(2):199-204. Epub 2007 Dec 10.

PMID:
18071030
[PubMed - indexed for MEDLINE]
16.

A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

Bech E, Lycke J, Gadeberg P, Hansen HJ, Malmeström C, Andersen O, Christensen T, Ekholm S, Haahr S, Höllsberg P, Bergström T, Svennerholm B, Jakobsen J.

Neurology. 2002 Jan 8;58(1):31-6.

PMID:
11781402
[PubMed - indexed for MEDLINE]
18.

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T; Laquinimod in Relapsing MS Study Group.

Neurology. 2005 Mar 22;64(6):987-91.

PMID:
15781813
[PubMed - indexed for MEDLINE]
19.
20.

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group.

Lancet. 2008 Jun 21;371(9630):2085-92. doi: 10.1016/S0140-6736(08)60918-6.

PMID:
18572078
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk